Mr. R...it all depends who their new friends are in and around White City...they say they want to keep it for themselves and they of course can and these days it's extremely easy to strike a contract manufacturing. However there is also the possibility of an AA with a Pharma whereby Avacta keeps the IP, does the ongoing research, trials and maintains trademarkets etc and the Pharma does all the sales and marketing/manufacturing (or contracts out). Avacta would gets a profit share or royalty plus possible performance payments and the Pharma gets first pick of future research/trial outcomes etc.
Wiggly...'If we now regard further commercial partnerships and license arrangements (both the therapeutics and interestingly other markets) we must surely be locked in active discussions not yet disclosed to the market...'
Why add this para to their website? What are they signalling...who are they signalling?
'We will no longer get to decide on lockdowns, they will.'...PURE PRESS AND SOCIAL MEDIA SCARE MONGERING...read the report and what is being voted on...nothing in it about lockdowns...again those who haven't read the detail believing the agenda driven few. The likes of Apple, Google, Amazon etc have far more control over your daily lives and these are unelected global entities who now dictate and disrupt without there being any accountability whatsoever. You should be screaming about the data harvesting which now controls pretty much everything we do...even Govts today make billions on selling data which they collected from you...grrrr...don't get me started on this one.
Is there a chance that there might not be a need for a DE if the full Dox is being taken straight into the tumour site before being released to do it's work and therefore the tumour might be strinking/dying faster than expected and therefore DE isn't necessary. I would assume DE is only necessary if the tumour isn't responding quickly enough and/or due to leakage/weakened strength. Why increase the dosage if the current dosage kills the tumour or is seen to be causing dramatic shrinkage... We won't know until we are told whether or not there has or is to be a further DE.
One would assume, as the manufacturer, the use of the word 'soon' was more than just a finger in the air type of comment...and their decision to take an investment stake surely is a sign they have some potential volume details and they've put two and two together on this one...
RE: never been as busy' amid M&A talks15 May 2022 17:26
Riesgo you might find the following interesting too:
Oncology research at Novartis Fighting cancer with next-generation therapeutics. The oncology team is developing a robust portfolio of treatments that destroy tumors selectively and strip away their defenses. They include: • Chimeric antigen receptor T (CAR-T) cell therapies: CAR-T cell therapies train T-cells from the patient's own immune system to attack and kill tumors. • Targeted Radioligand (RLT) therapies: RLT therapies attach radioactive isotopes to proteins that home in on cancer cell targets with high precision, thereby sparing healthy tissues. • Novel small molecules: We are developing novel small molecules against targets that were previously considered undruggable. https://www.novartis.com/research-development/research-disease-areas/oncology-research-novartis
POINT Biopharma is a clinical-stage pharmaceutical company focused on developing radioligands2 as precision medicines for the treatment of cancer. Avacta’s proprietary pre|CISIONTM chemistry can be used to modify a radioligand drug to form a tumour-activated prodrug. The prodrug form is inactive in circulation until it enters the tumour micro-environment where it is activated by an enzyme called fibroblast activation protein (or FAP) that is present in high abundance in most solid tumours but not in healthy tissue. Avacta’s pre|CISION™ technology therefore has the potential to improve the tolerability and achieve better clinical outcomes for patients compared with standard radiopharmaceuticals by targeting the radioligand treatment more specifically to cancer cells. https://avacta.com/license-agreement-with-point-biopharma-inc/
Beinthehead...you are right and we were told early on that Avacta would have limited input etc. That's not to say there might not be a new collaboration about to take place.
'In the partnership with ADC, Avacta will select the Affimers, after which ADC will be responsible for all preclinical research in relation to the creation of Affimer drug conjugates and subsequent clinical development. As all R&D costs are covered by ADC, Avacta benefits from limited upfront financial risk, with potential upside from the option on each target that could provide long-term milestones and royalties.'
It was the wording from the new article I found interesting...'accessible to our collaborators'...why move for a couple of flying visits from overseas collaborators....no I think this refers to collaborators within the White City area...and there is one obvious one who has also has locations around the World. “We are now at the heart of the innovative White City community in London, readily accessible to our collaborators around the world and poised to take Avacta to the next level in its evolution as a clinical stage biopharmaceutical company.”